Monday 3 October 2016

New CEO for Synoptics

Cambridge, UK: Synoptics, a world leader in the development and manufacture of innovative digital imaging systems for life science and clinical applications, is pleased to announce the appointment of Dr Brian Stammers as its new CEO. Brian’s wealth of experience in the life science industry will help guide Synoptics’s strategic direction to deliver innovative and commercially successful products.

As the CEO of Synoptics, which is part of the AIM quoted UK company Scientific Digital Imaging (SDI), Dr Stammers will oversee the commercial and technical direction of Synoptics’s three divisions, Syngene, Synbiosis and Synoptics Health.

Brian is a life science expert having been active in the sector for over 35 years. He has spent the past five years working as an International Trade Adviser for UK Trade & Investment (UKTI) helping life science companies realise their international business ambitions. Prior to this, he held several MD/CEO roles with major life science companies, including B&T (part of the E. Merck empire); Difco Laboratories (now part of Becton Dickinson) and Lab-M. He has also been the CEO of two successful university spin-out companies, where he raised venture finance.

Additionally, Brian has chaired and been president of UK Trade Association, The British Laboratoryware Association (BLWA) and was instrumental in merging the BLWA with GAMBICA, the Trade Association for Instrumentation, Control, Automation and Laboratory Technology. He is also a Freeman of the City of London.

Brian’s vast commercial expertise is underpinned by five years’ working as a research scientist in a leading pharmaceutical company, as well as a degree in Zoology and a Ph.D. in Parasitology both from the University of London.

Commenting on his appointment, Dr Stammers said: “I have worked closely with the Synbiosis division of Synoptics through UKTI for two years and I can see where my strategic guidance would make a significant difference to the commercial direction of the other divisions in the group. I’m looking forward to the opportunity of bringing that insight as the Synoptics group’s CEO.”

Mike Creedon, SDI’s CEO, added: “We are delighted to appoint such a capable CEO for the Synoptics Group. We believe Brian will make a meaningful contribution to building a thriving commercial product portfolio, which scientist across the globe will actively choose for improving the throughput and quality of their research.”

-Ends-